Holen Sie sich die Stockscreener-App
24.79
0.41%
0.10
Vorhandelsmarkt:
24.86
0.07
+0.28%
Schlusskurs vom Vortag:
$24.69
Offen:
$25.25
24-Stunden-Volumen:
705.77K
Relative Volume:
0.98
Marktkapitalisierung:
$975.44M
Einnahmen:
$734.86M
Nettoeinkommen (Verlust:
$5.14M
KGV:
198.32
EPS:
0.125
Netto-Cashflow:
$132.71M
1W Leistung:
-2.44%
1M Leistung:
+9.21%
6M Leistung:
+13.46%
1J Leistung:
-3.95%
1-Tages-Spanne:
$24.74
$25.60
1-Wochen-Bereich:
$23.47
$27.13
52-Wochen-Spanne:
$18.80
$27.64
Pacira Biosciences Inc Stock (PCRX) Company Profile
Firmenname
Pacira Biosciences Inc
Sektor
Telefon
650-242-8052
Adresse
2000 SIERRA POINT PARKWAY, BRISBANE, NJ
Compare PCRX vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PCRX
Pacira Biosciences Inc
|
24.79 | 971.50M | 734.86M | 5.14M | 132.71M | 0.125 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Barclays | Equal Weight |
| 2025-11-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-25 | Hochstufung | Truist | Hold → Buy |
| 2025-01-30 | Hochstufung | Truist | Sell → Hold |
| 2024-08-13 | Herabstufung | Truist | Buy → Sell |
| 2024-08-12 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2024-08-12 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-08-12 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-08-12 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2024-07-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2024-03-07 | Fortgesetzt | JP Morgan | Overweight |
| 2023-12-20 | Eingeleitet | Raymond James | Outperform |
| 2023-08-03 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2023-01-31 | Fortgesetzt | Wedbush | Outperform |
| 2022-10-21 | Fortgesetzt | Jefferies | Buy |
| 2022-01-03 | Fortgesetzt | JP Morgan | Overweight |
| 2021-07-26 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-04-21 | Fortgesetzt | JP Morgan | Neutral |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-02-11 | Herabstufung | Northland Capital | Outperform → Market Perform |
| 2021-01-21 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-09-21 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2020-07-06 | Bestätigt | Needham | Buy |
| 2020-05-27 | Eingeleitet | Guggenheim | Neutral |
| 2020-04-07 | Eingeleitet | Northland Capital | Outperform |
| 2020-03-20 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-02-24 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-24 | Eingeleitet | SunTrust | Buy |
| 2020-01-23 | Eingeleitet | SunTrust | Buy |
| 2019-11-06 | Eingeleitet | BTIG Research | Buy |
| 2019-06-11 | Eingeleitet | Barclays | Overweight |
| 2019-05-06 | Hochstufung | Mizuho | Underperform → Neutral |
| 2019-05-02 | Hochstufung | Stifel | Sell → Hold |
| 2019-02-01 | Herabstufung | Mizuho | Neutral → Underperform |
| 2018-08-06 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2018-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-21 | Bestätigt | Mizuho | Neutral |
| 2018-02-16 | Herabstufung | Needham | Buy → Hold |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
| 2018-01-04 | Bestätigt | Canaccord Genuity | Buy |
| 2018-01-03 | Eingeleitet | Leerink Partners | Mkt Perform |
Alle ansehen
Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten
Pacira BioSciences Mails Letter to Stockholders - The Manila Times
PACIRA BIOSCIENCES INC (NASDAQ:PCRX): A Value Stock Candidate with Margin of Safety - ChartMill
How Pacira’s Q1 2026 Results, EXPAREL Data and Proxy Battle May Impact Pacira BioSciences (PCRX) Investors - Sahm
Price-Driven Insight from (PCRX) for Rule-Based Strategy - Stock Traders Daily
Assessing Pacira BioSciences (PCRX) Valuation After Earnings Update And New EXPAREL Real World Data - Yahoo Finance
Pacira Biosciences Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Sales Forecast Maintained - Moomoo
Universal Beteiligungs und Servicegesellschaft mbH Boosts Stock Position in Pacira BioSciences, Inc. $PCRX - MarketBeat
Pacira BioSciences (PCRX) Return To Profitability Tests Bullish Growth Narratives - Sahm
Pacira BioSciences Reports Strong First Quarter Growth for EXPAREL - HarianBasis.co
MSN Money - MSN
PCRX Maintained by RBC Capital -- Price Target Raised to $24 - GuruFocus
PCRX Maintained by Needham -- Price Target Raised to $32 - GuruFocus
Pacira Q1 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y - The Globe and Mail
Royal Bank Of Canada Issues Positive Forecast for Pacira BioSciences (NASDAQ:PCRX) Stock Price - MarketBeat
Pacira BioSciences Stock (US6951271005): Analyst Rating Change and Price Move on May 1, 2026 - AD HOC NEWS
Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up Following Analyst Upgrade - MarketBeat
RBC Raises Price Target on Pacira Biosciences to $24 From $22, Keeps Sector Perform Rating - marketscreener.com
Vanguard Capital Management (PCRX) reports 2.09M-share stake in Pacira - Stock Titan
Vanguard Portfolio Management (PCRX) reports 2.59M shares, 6.38% stake - Stock Titan
Pacira (PCRX) Q1 2026 Earnings Call Transcript - AOL.com
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - Yahoo Finance
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q1 2026 Earnings Call Transcript - Insider Monkey
Pacira BioSciences' CFO Sold 12,941 Shares for $326,000 Before Its Q1 Earnings Release - The Motley Fool
Pacira BioSciences Inc (PCRX) Q1 2026 Earnings Call Highlights: Strong Product Growth Amidst Challenges - GuruFocus
Pacira outlines 2026 revenue guidance of $745M-$770M while advancing PCRX-201 Phase II milestones - MSN
Pacira BioSciences (NASDAQ:PCRX) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - MarketBeat
Pacira BioSciences Q1 2026 Earnings Call Transcript - MarketBeat
Pacira BioSciences Q1 Earnings Call Highlights - MarketBeat
Pacira BioSciences, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PCRX) 2026-04-30 - Seeking Alpha
Pacira BioSciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Pacira BioSciences : Corporate Sustainability Report (pacira corporate sustainability report 2024 v1 20260430) - marketscreener.com
Is Pacira BioSciences (PCRX) Undervalued After Q1 2026? GAAP EPS - GuruFocus
PCRX Sets Ambitious Goals for FY26 with Strong Clinical Focus - GuruFocus
Do options traders know something about Pacira BioSciences stock we don't? - MSN
Pacira BioSciences (PCRX) Reports Strong Q1 Revenue Growth - GuruFocus
Pacira Biosciences (NASDAQ:PCRX) Q1 2026 Results Beat Estimates as Key Pipeline Catalysts Near - ChartMill
Q1 2026 Pacira Biosciences Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PCRX) Pacira BioSciences, Inc. Posts Q1 Adjusted EPS $0.60 per Share, vs. FactSet Est of $0.55 - marketscreener.com
Earnings Flash (PCRX) Pacira BioSciences, Inc. Reports Q1 Revenue $177.4M, vs. FactSet Est of $171.8M - marketscreener.com
Pacira BioSciences (NASDAQ: PCRX) Q1 2026 revenue reaches $177M - Stock Titan
[8-K] Pacira BioSciences, Inc. Reports Material Event - Stock Titan
Pacira BioSciences 1Q EPS 7c >PCRX - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Pacira BioSciences Inc. (PCRX) Stock Rises on Q4 2025 Earnings - Quiver Quantitative
Pacira BioSciences Files Definitive Proxy Materials and Mails Letter to Shareholders - The Manila Times
Pacira to Report First Quarter 2025 Financial Results on Thursday May 8, 2025 - 富途牛牛
Is It Too Late to Buy Pacira BioSciences Inc (PCRX) After 4.3% R - GuruFocus
Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):